Basilea erhält von CARB-X Förderung von bis zu USD 2.7 Mio. für die Entwicklung eines Antibiotikums aus einer neuen Wirkstoffklasse

NEXT STORY
Osteoarthritis Treatment Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)
PREV STORY
Motorcycle Crash Survivor Reunites with EMS and Hospital Trauma Team Who Saved Her Life
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

iCAD announces positive study results comparing use of company’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to Mohs surgery in treatment of early-stage non-melanoma skin cancer

NASHUA, N.H., July 19, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider ...

author_avatar
NASDAQ Market News

NanoVibronix looks to expand use of its UroShield Due to the potential to impact comorbidities related to COVID-19 Crisis

author_avatar
NASDAQ Market News

INNATE PHARMA : Sixth DSMB meeting of the EffiKIR trial recommends continuation without modification

MARSEILLE, France, March 16, 2016 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - ...

author_avatar
NASDAQ Market News